Since SOCS3 showed the highest reduction in gene expression levels (i.e., 2.3-fold reduction compared to the healthy control cells receiving an unrelated nuclease), we chose to use this gene to monitor for any effects of mutated STAT3 allele disruption in the AD-HIES patient-derived cells. This evidence concerns the gene SOCS3 and Alzheimer disease.